Baili Tianheng announced that the company's self-developed T-Bren program for patients with locally advanced or metastatic biliary tract cancer that failed to be treated with platinum-containing chemotherapy with HER2 has been included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration and has been publicized. Up to now, T-Bren is conducting 20 clinical trials at home and abroad.

Baili Tianheng announced that the company's self-developed T-Bren program for patients with locally advanced or metastatic biliary tract cancer that failed to be treated with platinum-containing chemotherapy with HER2 has been included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration and has been publicized. Up to now, T-Bren is conducting 20 clinical trials at home and abroad.